The HER2-directed tyrosine kinase inhibitor lapatinib and the anti-HER2 monoclonal antibody trastuzumab prolong disease-free survival and overall survival [8] as well as suppressing tumor growth and metastasis in vitro and in vivo [6]. Here, ERBB2 is linked to neoplasm.